207 related articles for article (PubMed ID: 37591942)
1. Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
Gurule NJ; Malcolm KC; Harris C; Knapp JR; O'Connor BP; McClendon J; Janssen WJ; Lee FFY; Price C; Osaghae-Nosa J; Wheeler EA; McMahon CM; Pietras EM; Pollyea DA; Alper S
Leukemia; 2023 Oct; 37(10):2115-2124. PubMed ID: 37591942
[TBL] [Abstract][Full Text] [Related]
2. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract][Full Text] [Related]
3. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
[TBL] [Abstract][Full Text] [Related]
4. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene
Fei DL; Zhen T; Durham B; Ferrarone J; Zhang T; Garrett L; Yoshimi A; Abdel-Wahab O; Bradley RK; Liu P; Varmus H
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10437-E10446. PubMed ID: 30322915
[TBL] [Abstract][Full Text] [Related]
5. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
[TBL] [Abstract][Full Text] [Related]
6. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
Akef A; McGraw K; Cappell SD; Larson DR
PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
[TBL] [Abstract][Full Text] [Related]
7. Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice.
Kim SP; Srivatsan SN; Chavez M; Shirai CL; White BS; Ahmed T; Alberti MO; Shao J; Nunley R; White LS; Bednarski J; Pehrson JR; Walter MJ
Cell Rep; 2021 Aug; 36(9):109626. PubMed ID: 34469727
[TBL] [Abstract][Full Text] [Related]
8. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract][Full Text] [Related]
9. Decreased CD177
Alayed K; Meyerson HJ
Leuk Res; 2022 Jan; 112():106752. PubMed ID: 34896936
[TBL] [Abstract][Full Text] [Related]
10. Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract][Full Text] [Related]
11. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies.
Biancon G; Joshi P; Zimmer JT; Hunck T; Gao Y; Lessard MD; Courchaine E; Barentine AES; Machyna M; Botti V; Qin A; Gbyli R; Patel A; Song Y; Kiefer L; Viero G; Neuenkirchen N; Lin H; Bewersdorf J; Simon MD; Neugebauer KM; Tebaldi T; Halene S
Mol Cell; 2022 Mar; 82(6):1107-1122.e7. PubMed ID: 35303483
[TBL] [Abstract][Full Text] [Related]
12. A splice site-sensing conformational switch in U2AF2 is modulated by U2AF1 and its recurrent myelodysplasia-associated mutation.
Warnasooriya C; Feeney CF; Laird KM; Ermolenko DN; Kielkopf CL
Nucleic Acids Res; 2020 Jun; 48(10):5695-5709. PubMed ID: 32343311
[TBL] [Abstract][Full Text] [Related]
13. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
[TBL] [Abstract][Full Text] [Related]
14. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
[TBL] [Abstract][Full Text] [Related]
16. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing.
Okeyo-Owuor T; White BS; Chatrikhi R; Mohan DR; Kim S; Griffith M; Ding L; Ketkar-Kulkarni S; Hundal J; Laird KM; Kielkopf CL; Ley TJ; Walter MJ; Graubert TA
Leukemia; 2015 Apr; 29(4):909-17. PubMed ID: 25311244
[TBL] [Abstract][Full Text] [Related]
17. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
18. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
19. Impact of U2AF1 mutations on circular RNA expression in myelodysplastic neoplasms.
Wedge E; Ahmadov U; Hansen TB; Gao Z; Tulstrup M; Côme C; Nonavinkere Srivatsan S; Ahmed T; Jespersen JS; Schlotmann BC; Schöllkopf C; Raaschou-Jensen K; Ødum N; Kjems J; Bak RO; Walter MJ; Grønbæk K; Kristensen LS
Leukemia; 2023 May; 37(5):1113-1125. PubMed ID: 36922625
[TBL] [Abstract][Full Text] [Related]
20. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
Jenkins JL; Kielkopf CL
Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
